BiotechTube
Home/Pipeline/HBM2001

HBM2001

Inflammatory Bowel Disease (IBD)

DiscoveryActive (Global)

Key Facts

Indication
Inflammatory Bowel Disease (IBD)
Phase
Discovery
Status
Active (Global)
Company
Harbour BioMed

About Harbour BioMed

Harbour BioMed is a publicly traded biotech (HKEX: 02142) with a mission to deliver breakthrough medicines through its innovative antibody technology platforms. The company has successfully transitioned from a technology licensor to a clinical-stage entity with a maturing pipeline, evidenced by multiple out-licensing deals and strategic collaborations with major pharmaceutical companies. Its 'global for global' strategy leverages R&D centers in the US, Europe, and China to build a diversified portfolio of novel therapeutics.

View full company profile

Therapeutic Areas

ImmunologyOncologyMetabolic Diseases

Other Inflammatory Bowel Disease (IBD) Drugs

DrugCompanyPhase
Metabolite Delivery Platform (Therapeutic Programs)ClostraBioPre-clinical
ABO21009AboleIIs PharmaPhase 1
GlyHealth BiomarkersAvennaPre-clinical/Validation
GTI-850GSNO TherapeuticsPre-clinical
CK-0045Cytoki PharmaPre-clinical/Research
MV-010MV BioTherapeuticsPreclinical
NM81Numab InnovationPre-clinical
LIAISON® CalprotectinDiaSorinCommercial
SL-325Shattuck LabsPhase 2
SL-425Shattuck LabsPhase 1
VE202PureTech HealthPhase 2